Skip to main content
    I

    Innoviva Inc (INVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.49
    -0.54 (-2.84%)

    Market Cap: $1.35B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Innoviva Inc (INVA) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Innoviva (INVA) trades at 5.3x trailing earnings and 3.0x sales. Its P/E of 5.3x is below its 5-year median of 10.7x. Its forward P/E is 8.5x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 37.6% lower over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.

    MultipleValue
    P/E (trailing)5.3x
    Forward P/E8.5x
    Price to sales3.0x
    Price to book1.2x
    EV/EBITDA4.7x
    Price to FCF7.3x
    EV/FCF5.5x
    PEGN/A
    FCF yield13.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 41.8% below 9.1x and its P/S is 21.1% below 3.8x.

    MultipleCurrent5-year median10-year median
    P/E5.3x10.7x9.1x
    P/S3.0x3.4x3.8x
    P/B1.2x1.6xN/A
    Medians of month-end values through Oct 2026: 51 to 60 months (5-year) and 111 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 6.2x in 2021 to 59.8x in 2024.

    Year endPriceP/EP/SP/B
    2025$19.996.6x3.4x1.5x
    2024$17.3559.8x3.2x2.1x
    2023$16.0411.6x3.6x2.0x
    2022$13.2521.4x2.8x1.6x
    2021$17.256.2x3.7x3.4x
    2020$12.397.0x3.8x2.6x
    2019$14.169.9x5.7x5.1x
    2018$17.459.7x7.0x12.9x
    2017$14.1911.7x7.2xN/A
    2016$10.7020.6x9.1xN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About INVA

    What is INVA's forward P/E ratio?

    Innoviva has a forward P/E ratio of 8.5x.

    Is INVA stock overvalued?

    GNG's valuation label for INVA is Undervalued.

    What is INVA's price to sales ratio?

    Innoviva has a price to sales ratio of 3.0x.

    What is Innoviva's average P/E ratio over 5 years?

    Innoviva's median P/E over the last 5 years is 10.7x, from 51 month-end values through Oct 2026.